摘要
目的探讨舒肝散郁疗法治疗抑郁症的疗效及对神经递质含量的影响。方法 180例抑郁症患者随机分为对照组和观察组,每组90例。2组患者均接受心理干预治疗,此外,对照组口服氢溴酸西酞普兰片20 mg/d,观察组在对照组的基础上给予舒肝颗粒每次1袋,2次/d。8周为1个疗程。比较2组患者临床疗效以及神经递质含量变化。结果观察组的临床疗效显著优于对照组(z=2.63,P<0.05),且观察组总有效率明显高于对照组(χ~2=4.49,P<0.05)。2组患者治疗后HAMD评分和PSQI评分均显著下降(t分别为17.84,14.57,27.16,22.43,P<0.05),组间比较,观察组HAMD评分和PSQI评分均显著低于对照组(t分别为5.81,23.56,P<0.05)。2组患者治疗后ADL评分显著升高(t分别为34.97,28.74,P<0.05),组间比较,观察组ADL评分显著高于对照组(t=8.17,P<0.05)。2组患者治疗后NE、5-HT和DA水平均显著升高(t分别为25.52,21.47,22.31,18.44,11.67,9.86,P<0.05)。组间比较,观察组NE、5-HT和DA水平均显著高于对照组(t分别为7.50,7.42,7.41,P<0.05)。2组不良反应无显著差异(χ~2为2.28,P=0.13)。结论舒肝颗粒与SSRIs类药物联合应用能够明显改善抑郁症患者临床疗效,其机理有待进一步研究。
Objective To investigate the therapeutic effects of Shuganjieyu therapy on depression and its effects on neurotransmitter content of patients with depression. Methods A total of 180 patients with depression were randomly divided into control group ( n =90) and observation group ( n =90).The patients in both groups received psychological intervention. In addition,the patients in control group were treated by oral citalopram hydrobromide 20mg/d,however,the patients in observation group,on the basis of control group,were treated by Shugan granules, 1 bags once, twice a day,with a treatment course of 8 weeks for both groups. The clinical curative effects and the changes of neurotransmitter content were observed and comapred betyween the two groups. Results The clinical curative effects in observation group were superior to those in control group (z=2.63, P <0.05),moreover, the total effective rate in observation group was significantly higher than that in control group (χ^2=4.49, P <0.05). After treatment, HAMD and PSQI scores in both groups were decreased significantly ( P < 0.05 ),moreover,the HAMD scores and PSQI scores in observation group were significantly lower than those in control group ( P < 0.05). After treatment, the scores of ADL in both groups were increased significantly ( P <0.05),moreover,the ADL scores in observation group were significantly higher than those in control group ( P <0.05). In addition the levels of NE, 5-HT and DA in both groups were increased significantly after treatment ( P <0.05),furthermore, the levels of NE, 5-HT and DA in observation group were significantly higher than those in control group ( P <0.05). However there was no significant difference in the incidence rate of adverse reactions between the two groups ( P >0.05). Conclusion Shugan granules combined with SSRIs drugs can significantly improve the clinical curative effects on depression, and its action mechanism needs to be researched further.
作者
刘肖莉
张立霞
刘照佩
鲁晓辉
卢红燕
房晓萌
LIU Xiaoli;ZHANG Lixia;Liu Zhaopei(Department of Psychology,The Third Hospital of Shijiazhuang City,Hebei,Shijiazhuang 050011,China)
出处
《河北医药》
CAS
2019年第8期1207-1210,共4页
Hebei Medical Journal
基金
河北省卫生厅指导项目(编号:ZD20140041)
河北省重点研发计划项目(编号:18277795D)
